Evolocumab (Repatha) is an injectable monoclonal antibody that reduces LDL cholesterol levels. A limited quantity of LDL cholesterol is extracted from circulative blood when PCSK9-bound LDLR is degraded upon internalization in liver cells. Evolocumab competitively binds PCSK9 away from LDLR complexes, which allows LDLR to be recycled, returning to the surface and clearing additional molecules of LDL cholesterol. ad2drug pathwayPW:0000754Pathway Ontology10.1211/PJ.2015.20068181DOIPCSK9 inhibitors: the next cholesterol-lowering blockbusters?The Pharmaceutical Journal2015Dorey, EmmahepatocyteCL:0000182Cell Typealtered cholesterol biosynthetic pathwayPW:0000752Pathway Ontologyaltered cholesterol transport pathwayPW:0001347Pathway Ontology